Using a mouse model, scientists from the RIKEN-Max Planck Joint Research Center for Systems Chemical Biology and a number of other institutes have identified a sugar molecule that reduced the inflammatory response and progress of emphysema, a common component of chronic obstructive pulmonary disease (COPD). According to Naoyuki Taniguchi, the leader of the group, this discovery could lead to the development of drugs based on glycans—biological sugar molecules—for the treatment of diseases such as COPD, which is the fourth leading cause of death worldwide.
As part of the research group’s work to explore the roles of sugar molecules in health and disease, they found that keratan sulfate, a large negatively charged saccharide found in the small airway of the lung, is decreased in mice that have been exposed to cigarette smoke. They wondered if this decrease might be associated with the damage that smoking causes to the lung. Taniguchi says, “We are not absolutely sure of the mechanism through which smoking leads to a reduction in keratan sulfate, but felt that clearly the reduction is important in thinking about glycan-based strategies for combating emphysema and COPD.”
They wondered whether the keratan sulfate might be playing a protective role in COPD. To test the hypothesis, they prepared a repeating disaccharide element of keratan sulfate, named L4, and administered it into two mouse models of emphysema—one a model of emphysema triggered by the enzyme elastase, and the other an exacerbation of smoking-induced emphysema triggered by LPS, a toxin found in bacterial cell walls.
In the first model, they found that that treatment with L4 prevented destruction of the alveoli—the small air sacs in lungs that are used to exchange gases, and in addition that it reduced the infiltration of a type of white blood cell called neutrophils, which is symptomatic of an inflammatory response, as well as levels of inflammatory cytokines and tissue-degrading enzymes. Although L4 was shown to inhibit these enzymes, they did not find any ability of L4 to directly reduce the production of cytokines or reactive oxygen species, so concluded that the action was also being done indirectly, through mechanisms involving the neutrophils.
In the exacerbation model, they found that the L4 administration prevented the influx of neutrophils. According to Taniguchi, “We found that L4 was as effective as dexamethasone in reducing neutrophil infiltration. This is very exciting, because dexamethasone, the treatment currently used for COPD, is a steroid medication that can have serious side effects and can in some cases make the outcome worse. It will be exciting if we can show that L4—a sugar molecule which we found had no adverse effects in the mice even at high doses—can be used as a treatment for this condition, which exerts a tremendous health burden.”
According to Taniguchi, there is still work to be done in the area. “We plan now to try to determine exactly how L4 blocks neutrophil migration, by finding a target receptor protein, and how L4 can suppress inflammation in vivo, as this could give us important insights into the mechanism of COPD progression and how it can be halted.”
Receive an email update when we add a new COPD article.
The Latest on: COPD
via Google News
The Latest on: COPD
- Does Diet Have an Effect on COPD Prevalence and Incidence?on July 10, 2020 at 1:58 pm
The focus on curbing COPD prevalence has largely focused on smoking cessation, but there are other factors, including diet, that can contribute to the risk of developing COPD.
- COPD has substantial physical and psychosocial impact on younger patients, survey revealson July 10, 2020 at 8:23 am
Results of a global survey of 1,375 adults aged at least 45 years old and living with Chronic Obstructive Pulmonary Disease (COPD) in 11 countries have been published in COPD: Journal of Chronic ...
- Making a Difference with COPDon July 9, 2020 at 1:15 pm
Janice Cotton was diagnosed with COPD 20 years ago. In her story, she talks about how COPD inspired her to be a better person.
- BUSINESS WIRE: Perceived burden of disease is greater in younger people living with COPD, global survey revealson July 9, 2020 at 7:22 am
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH. COPD impacts younger patients’ daily activities more significantly Younger patients ...
- Perceived burden of disease is greater in younger people living with COPD, global survey revealson July 9, 2020 at 7:13 am
COPD impacts younger patients' daily activities more significantly Younger patients feel more negative about their disease Younger patients want and need more support from HCPs to achieve ...
- Global COPD Telemonitoring System Market 2020 Industry Segmentation, CAGR Status, Leading Trends, and Forecast To 2026on July 9, 2020 at 2:30 am
The report provides rational insights along with historical and forecast data to aid in better understanding of ...
- How people with COPD can breathe easier during the summer heaton July 7, 2020 at 1:48 pm
The heat and humidity can be dangerous for those who suffer from COPD. The lung experts at Temple Health offer tips to make the season more bearable.
- Hospitalized Patients With COPD at Greater Risk of OSA, Insomniaon July 7, 2020 at 9:33 am
Hospitalized patients with chronic obstructive pulmonary disease (COPD) were shown to be at greater risk of obstructive sleep apnea (OSA) and insomnia than those without COPD, with worse outcomes for ...
- Health expenditures considerable for asthma, COPD in U.S. workerson July 6, 2020 at 2:22 pm
The annualized total medical expenditures for asthma and chronic obstructive pulmonary disease (COPD) are $7 billion and $5 billion among U.S. workers, respectively, according to research published in ...
via Bing News